The GenAc platform proposes to select and produce specific antibodies against therapeutic targets using phage display. This activity is based on synthetic human antibody libraries build at the IRCM. This development of monoclonal antibodies is proposed in priority to the Montpellier SIRIC community, but is also opened to external groups in France if resources are available.
The proposed approach allows notably to select cross-reacting antibodies (mouse-human target for example) to evaluate toxicity and activity in any pre-clinical model (xenografted, syngeneic, spontaneous, chemically induced or transgenic mouse model). Moreover this platform does not use animals for producing antibodies, alleviating ethical limitations, immune restriction, and in vivo toxicity of the antigen. Finally, because of the in vitro approach used, this allows a much faster development time.
Conditions of access:
Please fill in the Project form to collaborate with the Plateform and send it completed to: GenAc@icm.unicancer.fr
Applications are submitted to a scientific committee comprising one scientist of each institute participating to the SIRIC which will validate the feasibility and prioritise the projects. This committee meets regularly:
See also: www.ircm.fr/genac
Operations Manager: Myriam Chentouf: email@example.com